The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

Study led by Mount Sinai researcher shows sotagliflozin is the only drug in its class to demonstrate these results ...

Groundbreaking research exposes how diabetes damages kidneys, offering hope through early detection and innovative prevention ...

Elevated serum fibroblast growth factor 23 levels at baseline are linked to a 29% increased risk for diabetic kidney disease, a recent observational study found.

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

Ozempic, Wegovy, Saxenda, Trulicity: These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for fo ...

A well-known class of drugs used to manage type 2 diabetes and control weight could offer hope for patients who also struggle ...

Our study thus confirmed what was found in people of African descent in the US: the genetic origin underpinning the excess ...

A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.

The National Institute for Nephrology Dialysis and Transplantation (NINDT) has planned a series of events to mark this ...

For individuals with type 1 diabetes, intraindividual body weight variability, or body weight cycling, is associated with an ...